Abbonarsi

Endocytoscopy for assessing histologic inflammation in ulcerative colitis: development and prospective validation of the ELECT (ErLangen Endocytoscopy in ColiTis) score (with videos) - 13/12/22

Doi : 10.1016/j.gie.2022.08.023 
Francesco Vitali, MD 1, Nadine Morgenstern, MD 1, Markus Eckstein, MD 2, Raja Atreya, MD, Prof 1, Maximilian Waldner, MD, Prof 1, Arndt Hartmann, MD, Prof 2, Markus F. Neurath, MD, Prof 1, Timo Rath, MD, Prof 1,
1 Department of Medicine I, Division of Gastroenterology, Ludwig Demling Endoscopy Center of Excellence, University Hospital of Erlangen, University Erlangen-Nürnberg, Erlangen, Germany 
2 Institute of Pathology, University Hospital of Erlangen, University Erlangen-Nürnberg, Erlangen, Germany 

Reprint requests: Timo Rath, MD, Division of Gastroenterology, Ludwig Demling Endoscopy Center of Excellence, University Hospital of Erlangen, Ulmenweg 18, 91054 Erlangen, Germany.Division of GastroenterologyLudwig Demling Endoscopy Center of ExcellenceUniversity Hospital of ErlangenUlmenweg 18Erlangen91054Germany

Abstract

Background and Aims

Apart from endoscopic healing as an established treatment goal in patients with inflammatory bowel disease (IBD), histologic remission is an emerging endpoint that might even better predict disease outcome, especially in ulcerative colitis (UC). Within this study, we aimed to evaluate whether endocytoscopy (EC) as an in vivo contact microscopy technology can accurately assess histologic inflammation and predict the further course of disease in UC patients.

Methods

Initially, a new and intuitive EC score reflecting the entire spectrum of microscopic disease activity in UC was consensually developed. Subsequently, this score was independently validated in 46 patients with UC who underwent close-meshed follow-up during which major adverse outcomes (MAOs; defined as disease flare, IBD-related hospitalization, IBD-related surgery, necessity for initiation or escalation therapy) were recorded. Results of EC grading of inflammatory activity were compared against 2 validated histologic scores in UC. Diagnostic performance of endoscopic remission under white-light endoscopy (Mayo Endoscopic Score and Ulcerative Colitis Endoscopic Index of Severity), EC, and histology were compared for the prediction of MAOs.

Results

Endocytoscopic assessment of inflammatory activity in UC based on the newly developed ErLangen Endocytoscopy in ColiTis score showed strong correlation with histopathologic scoring (Robarts Histopathology Index, r = .70; Nancy Histologic Index, r = .73) and was superior to white-light endoscopy for grading of microscopic disease activity, with a sensitivity of 88%, specificity of 95.2%, and area under the curve of .916. Furthermore, EC exhibited a high interobserver agreement for in vivo grading of microscopic inflammation and was comparably accurate as histopathology for forecasting the occurrence of MAOs in UC.

Conclusions

Endocytoscopic grading of inflammatory activity along a newly developed scoring system enabled real-time histology in UC patients and better predicted clinical outcome in UC patients than endoscopic remission.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : EC, ELECT, HD, IBD, MAO, MES, NHI, RHI, UC, UCEIS, WLE


Mappa


 DISCLOSURE: Dr Hartmann: Advisory board for BMS, MSD, Roche, Cepheid, Qiagen, Janssen, Astra Zeneca, Agilent, Lilly, Phäon, Ipsen, and Diaceutics; Speaker honoraria from, BMS, MSD, Roche, Astra Zeneca, Boehringer, Ingelheim, Abbvie, Janssen, Pfizer, Ipsen, and Diaceutics; Consultant for BMS, MSD, Roche, AstraZeneca, Boehringer Ingelheim, Abbvie, Janssen, Pfizer, Ipsen, and Diaceutics; Clinical trials for Janssen, Cepheid, AstraZeneca, and Roche; Research support from Illumina, Cepheid, Biontech, Roche, Janssen, Nanostring, and Astra Zeneca. All other authors disclosed no financial relationships.


© 2023  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 97 - N° 1

P. 100 - gennaio 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Timing of colonoscopy in acute lower GI bleeding: a multicenter retrospective cohort study
  • Yasutoshi Shiratori, Naoki Ishii, Tomonori Aoki, Katsumasa Kobayashi, Atsushi Yamauchi, Atsuo Yamada, Jun Omori, Taiki Aoyama, Naoyuki Tominaga, Yoshinori Sato, Takaaki Kishino, Tsunaki Sawada, Masaki Murata, Akinari Takao, Kazuhiro Mizukami, Ken Kinjo, Shunji Fujimori, Takahiro Uotani, Minoru Fujita, Hiroki Sato, Sho Suzuki, Toshiaki Narasaka, Junnosuke Hayasaka, Tomohiro Funabiki, Yuzuru Kinjo, Akira Mizuki, Shu Kiyotoki, Tatsuya Mikami, Ryosuke Gushima, Hiroyuki Fujii, Yuta Fuyuno, Naohiko Gunji, Yosuke Toya, Kazuyuki Narimatsu, Noriaki Manabe, Koji Nagaike, Tetsu Kinjo, Yorinobu Sumida, Sadahiro Funakoshi, Kiyonori Kobayashi, Tamotsu Matsuhashi, Yuga Komaki, Kuniko Miki, Kazuhiro Watanabe, Kazuki Yamamoto, Takaaki Yoshimoto, Ayaka Takasu, Takashi Ikeya, Fumio Omata, Katsuyuki Fukuda, Mitsuru Kaise, Naoyoshi Nagata
| Articolo seguente Articolo seguente
  • Second-generation distal attachment cuff for adenoma detection in screening colonoscopy: a randomized multicenter study
  • Katharina Zimmermann-Fraedrich, Susanne Sehner, Thomas Rösch, Jens Aschenbeck, Andreas Schröder, Stefan Schubert, Thomas Liceni, Alireza Aminalai, Wolfgang Spitz, Ulrich Möhler, Frank Heller, Rüdiger Berndt, Cordula Bartel-Kowalski, Katrin Niemax, Wolfgang Burmeister, Guido Schachschal

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.